Get the Stockscreener App
472.21
3.52%
-17.21
Pre-market:
472.21
United Therapeutics Corp stock is traded at $472.21, with a volume of 545.30K.
It is down -3.52% in the last 24 hours and down -7.93% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$489.42
Open:
$472.72
24h Volume:
545.30K
Relative Volume:
1.06
Market Cap:
$20.25B
Revenue:
$3.17B
Net Income/Loss:
$1.29B
P/E Ratio:
17.43
EPS:
27.0947
Net Cash Flow:
$1.01B
1W Performance:
-5.04%
1M Performance:
-7.93%
6M Performance:
-11.21%
1Y Performance:
+7.63%
1-Day Range:
$468.97
$481.32
1-Week Range:
$468.97
$500.05
52-Week Range:
$409.07
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
472.21 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Why United Therapeutics (UTHR) Shares Are Falling Today - finance.yahoo.com
A Look at United Therapeutics Corp (UTHR) After 3.5% Decline -- GF Value $427.97 vs Price $472.21 - GuruFocus
United Therapeutics CEO Rothblatt sells $4.67m in stock after option exercise - Investing.com Nigeria
Form 4 United Therapeutics Corporation For: 24 September - Investing.com India
Form 4 United Therapeutics Corporation For: 24 September By Investing.com - Investing.com Canada
After exercising 9,500 options, family trusts sold United Therapeutics (UTHR) shares under a pre-arranged plan. - Stock Titan
United Therapeutics Falls as Goldman Sachs Sets $321 Price Target - citybiz
United Therapeutics Corporation (UTHR) stock price, news, quote and history - Yahoo Finance UK
United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR) - Seeking Alpha
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate - ChartMill
Goldman Sachs initiates United Therapeutics stock with sell rating - Investing.com
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Under a pre-arranged plan, United Therapeutics (UTHR) CEO’s family trusts exercise 9,500 options and sell the shares. - Stock Titan
United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth (NASDAQ:UTHR) - Seeking Alpha
United Therapeutics Corporation at Bernstein Healthcare Forum Transcript - GuruFocus
United Therapeutics CEO Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $4.7m in stock - Investing.com
United Therapeutics (UTHR) CEO sells shares at nearly $500 each - Stock Titan
United Therapeutics CEO Rothblatt sells $4.7m in UTHR shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation For: 22 September By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $4.7m in UTHR shares - Investing.com
CEO stock sale near $500 a share was preplanned, United Therapeutics (UTHR) says - Stock Titan
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock - ChartMill
United Therapeutics EVP Paul A. Mahon Executes Stock Options and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
United Therapeutics (UTHR) CEO sells 9,500 shares under preset plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) general counsel sells shares near $500 - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO exercises 9,500 options and sells matching shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO exercises options and sells stock under preset plan - Stock Titan
Director Nilda Mesa Sells 228 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics (NASDAQ: UTHR) CEO exercises 9,500 options, then sells the shares under preset plan - Stock Titan
United Therapeutics (UTHR) director exercises options, then sells shares - Stock Titan
United Therapeutics CEO Martine Rothblatt sells $4.7m in shares By Investing.com - Investing.com Nigeria
United Therapeutics Corporation at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $4.7m in shares - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace? - Yahoo Finance
Rothblatt Executes Stock Option Exercise and Multiple Share Sales Under 10b5-1 Plan at United Therapeutics - kalkinemedia.com
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia
United Therapeutics at Cantor healthcare conference: fibrosis push widens By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock - investing.com
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares in preset plan - Stock Titan
United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart
United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView
United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan
United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):